Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 31, 2015 4:04 AM ET


Company Overview of Nivalis Therapeutics, Inc.

Company Overview

Nivalis Therapeutics, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of product candidates for patients with cystic fibrosis (CF). CF is a life-shortening genetic disease. Its lead product candidate is N91115, a small molecule that is in Phase Ib clinical trial, which addresses a defect in cystic fibrosis transmembrane conductance regulator (CFTR), resulting from mutations in the CFTR gene. The company was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. Nivalis Therapeutics, Inc. was founded in 2007 and is headquartered in Boulder, Colorado.

3122 Sterling Circle

Suite 200

Boulder, CO 80301

United States

Founded in 2007

24 Employees



Key Executives for Nivalis Therapeutics, Inc.

Chief Operating Officer and Executive Vice President
Age: 57
Total Annual Compensation: $413.8K
Vice President of Research & Discovery
Age: 53
Total Annual Compensation: $345.7K
Compensation as of Fiscal Year 2014.

Nivalis Therapeutics, Inc. Key Developments

Nivalis Therapeutics, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Nivalis Therapeutics, Inc. announced unaudited earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $5,852,000 compared to $3,957,000 a year ago. Net loss was $5,852,000 or $1.41 per basic and diluted share compared to $4,189,000 or $25.70 per basic and diluted share a year ago. The increased loss was the result of the initiation of the Phase 1b clinical trial, which began in the first quarter of 2015, and related development costs for N91115. For the six months, the company reported loss from operations of $10,167,000 compared to $8,347,000 a year ago. Net loss was $10,166,000 or $3.19 per basic and diluted share compared to $8,539,000 or $52.71 per basic and diluted share a year ago.

Nivalis Therapeutics, Inc.(NasdaqGM:NVLS) added to NASDAQ Composite Index

Nivalis Therapeutics, Inc. has been added to Nasdaq Composite Index.

N30 Pharmaceuticals, Inc. has Changed its Name to Nivalis Therapeutics, Inc

N30 Pharmaceuticals, Inc. changed its name to Nivalis Therapeutics, Inc.

Similar Private Companies By Industry

Company Name Region
rEVO Biologics, Inc. United States
CytoVale Inc. United States
Aubrey Inc. United States
Sanofi Pasteur VaxDesign Corporation United States
Osprey Biomedical Corp. United States

Recent Private Companies Transactions

Private Placement
November 18, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Nivalis Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at